Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 220 cancer 143 forskning & utveckling 115 hjärta/kärl 99 diabetes 61 andningsvägar 40 mage/tarm 15 neurovetenskap 12 FDA 10 onkologi 8 seroquel 7 delårsrapport 7 infektion 7 astma 7 akut kranskärlssjudom 6 medimmune 6 Observationsstudie 6 forskning 6 ledning 5 bokslutsrapport 5 vandetanib 5 Tagrisso 5 influensavaccin 5 forxiga 5 egfr-testning 5 RWE 5 motavizumab 5 naloxegol 5 karolinska institutet 4 fostamatinib 4 fluenz 4 ledgångsreumatism 4 bristol-myers squibb 4 lungcancer 4 antibiotika 4 olaparib 4 seroquel xr 4 tc-5214 4 egentlig depression 3 subvention 3 osimertinib 3 CVD-REAL 3 vimovo 3 japan 3 produkt 3 gefitinib 3 pathos 3 slusg 3 kroniskt obstruktiv lungsjukdom 3 astra tech 3 selumetinib 3 anders ekblom 3 crestor® 3 antibiotikaresistens 3 styrelsen 3 kina 2 smärta 2 byetta 2 opioider 2 individanpassad behandling 2 seroquel xr (quetiapin fumarat) 2 entocort 2 astrazenca 2 axanum 2 patenttvist 2 registerstudie 2 Real World evidence 2 ardea biosciences 2 typ2diabetes 2 corporate 2 tyskland 2 targacept 2 seroquel xl 2 acalabrutinib 2 almedalen 2 benralizumab 2 life science 2 bydureon 2 recentin 2 ticagrelor 2 saturn 2 epanova 2 återfall 2 kvartalsrapport 2 Brilique 2 läkemedelsförmånen 2 mdd 2 samarbete 2 klopidogrel 2 caprelsa 2 fulvestrant 2 confirm 2 slusg stipendium 2 monoterapi 1 den amerikanska läkemedelsmyndigheten 1 skelettmetastaser 1 roger henriksson 1 produktionsanläggning 1 gikt 1 cardiologföreningen 1 ovarian cancer 1 merck-avtal 1 savor 1 årsredovisning 2010 1 non-executive director 1 iressa 1 nytt läkemedel mot lungcancer 1 behandling lungcancer 1 målstyrt läkemedel 1 EGFR 1 nytt läkemedel lungcancer 1 cediranib 1 bevacizumab 1 scilifelab 1 yngre forskare 1 päivi tolstoy 1 tobias ankner 1 hans andersson 1 syntetisk kemi 1 torrent pharma 1 varumärkta generika 1 saxagliptin 1 blodsockerkontroll 1 blodsockerfall 1 viktökning 1 esc 1 ldl-c 1 gonorré 1 sepsis 1 livskvalitet lungcancer 1 ipass 1 lungcancersymtom 1 mcrc 1 complete response letter (crl) 1 u.s. food and drug administration (fda) 1 generiskt esomeprazolmagnesium 1 kanadensiska hälsovårdsministeriet 1 apotex inc (notice of compliance 1 noc) 1 internationell konkurrens 1 nikotinkanalsblockerare 1 läkemedel 1 DAISY 1 subventioner 1 UCR 1 zibotentan 1 biokemiska markörer 1 egfr-muterad 1 cytofab 1 azd9773 1 eurika 1 kombiglyze xr 1 klinisk forsk 1 pegasus 1 produktionschef 1 berzeliussamlingen 1 nya läkemedel 1 right honourable baroness shriti vadera 1 certriad 1 astrazeneca lund 1 arbetsmarknadsdagar 1 registreringsansökan 1 kastrationsresistent 1 fas 3-studie 1 hormonresistent 1 budesonid 1 mobil-app 1 opioidbehandling 1 nktr-118 1 forskningsportfölj 1 skatteärende 1 denosumab 1 amylin 1 patologi 1 NSCLC 1 egfr mutation 1 egfr positiv 1 komboglyze 1 caz-avi 1 hälsoekonomiska data 1 delårsrapport januari-september 2011 1 patientundersökning 1 david brennan 1 hudinfektioner 1 medicon village 1 translationell 1 illumina 1 årsredovisning 2011 1 antibiotikum 1 flumist 1 kvadrivalent 1 quetiapin fumarat 1 citizen petitions 1 renaissance 4 1 renaissance 5 1 formuleringspatent 1 citizens petition 1 prismodell 1 lesinurab 1 the medicines company 1 nda 1 amend 1 amylin pharmaceuticals 1 mdr-tb 1 mikael agaton 1 grymt fett 1 tonårshjärnan 1 per hamid ghatan 1 grymt fett en filmserie om tonårshjärnan 1 exacerbationer 1 pascal soriot 1 säsongsinfluensavaccin för barn som nässpray 1 säsongsinfluencavaccin 1 barninfluensavaccin 1 nässprayvaccin 1 influensanässpray 1 jonas bergh 1 bröstcancer utmärkelse 2012 1 sjukhusinfektioner 1 zinforo 1 mjukdelsinfektioner 1 ceftarolinfosamil 1 max planck institute 1 magnus björsne 1 per alfredsson 1 remissvar prismodell 1 pris läkemedel 1 strategiska centra 1 forsknings - och utvecklingscentra 1 bioläkemedel 1 tre strategiska centra 1 aks 1 exenatide 1 glp-1 agonister 1 cancerregister 1 svenska lungcancerstudiegruppen 1 non-small-cell lungcancer 1 motivationsstöd 1 patient websida 1 sekundärprevention 1 patientstöd 1 fluenz tetra 1 metreleptin 1 lipodystrofi 1 lesinurad 1 farxiga 1 xigduo 1 myalept 1 ann cairns 1 akuta koronara syndrom 1 metabola sjukdomar 1 immunoterapier 1 advaxis 1 sommarforskarskola 1 non-small cell lung cancer 1 astma/kol 1 gensekvensering 1 oic 1 hjärt-och kärlsjukdom 1 hjärinfarkt 1 biohub 1 bioventurehub 1 elisabeth björk 1 antaros 1 hha 1 healthy heart africa 1 världsdiabetesdagen 2014 1 moventig 1 Lynparza 1 opioidorsakad 1 pegasus-timi 1 e-brilique 1 Uppsala Clinical Research Center 1 mobiltelefonapplikation 1 SUPPORT-studien 1 ordnat införande Almedalen 1 QTERN 1 Zavicefta 1 moderna therapeutics 1 SvFP 1 kyntheum 1 brodalumab 1 Imfinzi 1 durvalumab 1 CVD-REAL Nordic 1 osimertinub 1 världsastmadagen 1 PACEHR 1 svår astma 1 Katarina Ageborg 1 norge 1 VD AstraZeneca Sverige AB 1 innovation 1 eu 1 sponsring 1 patent 1 produktion 1 lund 1 forskare 1 stipendier 1 usa 1 hjärtinfarkt 1 stroke 1 kol 1 influensa 1 depression 1 antidepressiva läkemedel 1 tlv 1 beslut 1 alzheimers 1 äggstockscancer 1 södertälje 1 högkostnadsskyddet 1 collaboration 1 halvårsrapport 1 forskarstipendium 1 schizofreni 1 merck 1 läkemedelsforskning 1 pfizer 1 psoriasis 1 bakterier 1 karolinska universitetssjukhuset 1 artros 1 pa 1 delårsrapport januari - mars 1 h1n1 1 r&d 1 mölndal 1 generiska läkemedel 1 typ 2-diabetes 1 styrelseordförande 1 gener 1 apollo 1 hälsoekonomi 1 halvårsresultat 1 pet 1 mrsa 1 ny indikation 1 diagnostik 1 förstoppning 1 kranskärlsjukdom 1 invasiv behandling 1 journal of clinical oncology 1 avancerad hormonkänslig bröstcancer 1 first studien 1 dapagliflozin 1 asco 1 konkurrenskraften 1 läkemedelsforskningen 1 forskarkarriärer 1 stipendieprogram 1 rosuvastatinkalcium 1 hyperkolesterolemi 1 pluto-studien 1 vimovotm 1 nsaid 1 pozen 1 sumitomo 1 american college of rheumatology 1 2009 annual scientific meeting in philadelphia 1 leif johansson 1 zactima (vandetanib) 1 toprol-xl 1 vaccinet 1 inflammation 1 jan lundberg 1 stemi 1 rosuvastatin 1 arimidex 1 anastrozol 1 atac 1 bypass 1 kolorektalcancer 1 sjukhussjuka 1 avancerad bröstcancer 1 avastin 1 kvalitetsregister 1 blodförgiftning 1 ämnesomsättningssjukdomar 1 jupiter-studien 1 ämnesomsättningssjukdomar (emdac) 1 jupiter 1 faslodex (fulvestrant) 1 Visa alla taggar
AstraZeneca tillkännager organisationsförändringar

AstraZeneca tillkännager organisationsförändringar

Pressmeddelanden   •   Jan 07, 2019 14:02 CET

AstraZeneca meddelar idag organisationsförändringar för att stödja fortsatt vetenskaplig innovation och kommersiell framgång inom de huvudsakliga terapiområdena, i samband med att bolaget går in i en ny fas i dess strategiska utveckling. Som en del av förändringarna meddelas att den mycket erkända onkologiforskaren José Baselga också rekryterats.

Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease

Bevespi Aerosphere approved in the EU for chronic obstructive pulmonary disease

Pressmeddelanden   •   Dec 20, 2018 15:00 CET

AstraZeneca today announced that the European Commission (EC) has approved Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in a pressurised metered-dose inhaler (pMDI) as a maintenance dual bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer

Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer

Pressmeddelanden   •   Dec 20, 2018 08:14 CET

AstraZeneca and MSD’s Lynparza significantly improved objective response rate compared to chemotherapy in platinum-sensitive relapsed patients who had two or more prior lines of chemotherapy

Phase III OLYMPUS and ROCKIES trials for roxadustat met their primary endpoints in chronic kidney disease patients with anaemia

Phase III OLYMPUS and ROCKIES trials for roxadustat met their primary endpoints in chronic kidney disease patients with anaemia

Pressmeddelanden   •   Dec 20, 2018 08:02 CET

AstraZeneca today announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney disease (CKD) that are either non-dialysis-dependent or dialysis-dependent, respectively.

Lynparza approved by US FDA for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer

Lynparza approved by US FDA for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer

Pressmeddelanden   •   Dec 19, 2018 19:47 CET

AstraZeneca and Merck & Co. US today announced that the FDA has approved Lynparza for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.....

Roxadustat approved in China for the treatment of anaemia in chronic kidney disease patients on dialysis

Roxadustat approved in China for the treatment of anaemia in chronic kidney disease patients on dialysis

Pressmeddelanden   •   Dec 18, 2018 10:16 CET

AstraZeneca today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. has now received formal marketing authorisation from the National Medical Products Administration for roxadustat, a first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor and new oral treatment for patients with anaemia caused by chronic kidney disease that are on dialysis.

AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines

AstraZeneca and Cancer Research UK launch Functional Genomics Centre to accelerate the discovery of new medicines

Pressmeddelanden   •   Dec 10, 2018 08:45 CET

AstraZeneca today announced a new collaboration with Cancer Research UK to launch a centre of excellence in genetic screening, cancer modelling and big data processing aimed at accelerating the discovery of new cancer medicines.

Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer

Update on the Phase III EAGLE trial of Imfinzi and tremelimumab in advanced head and neck cancer

Pressmeddelanden   •   Dec 07, 2018 08:02 CET

AstraZeneca and MedImmune today announced overall survival results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trial evaluating Imfinzi monotherapy or Imfinzi in combination with tremelimumab versus standard-of-care chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma......

New long-term data on Calquence presented at ASH 2018

New long-term data on Calquence presented at ASH 2018

Pressmeddelanden   •   Dec 04, 2018 08:00 CET

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, have presented new, long-term follow-up results for Calquence (acalabrutinib) in patients with relapsed or refractory mantle cell lymphoma (MCL).

NT-rådet rekommenderar Imfinzi (durvalumab) som ett behandlingsalternativ vid icke småcellig lungcancer

NT-rådet rekommenderar Imfinzi (durvalumab) som ett behandlingsalternativ vid icke småcellig lungcancer

Pressmeddelanden   •   Nov 28, 2018 13:47 CET

NT-rådets (Rådet för nya terapier) rekommendation till landstingen är att Imfinzi (durvalumab) kan införas som ett behandlingsalternativ vid icke småcellig lungcancer (NSCLC). Beslutet innebär att NT rådet ser ett visst värde i behandlingsalternativet men låter landsting och regioner själva avgöra i vilken mån det ska införas som ett behandlingsalternativ.

AstraZeneca presents clinical research advances for blood cancer patients at 2018 American Society of Hematology Annual Meeting

AstraZeneca presents clinical research advances for blood cancer patients at 2018 American Society of Hematology Annual Meeting

Pressmeddelanden   •   Nov 27, 2018 08:02 CET

AstraZeneca, together with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will present 27 abstracts, including six oral presentations, at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego, USA, December 1-4.

US FDA grants Fasenra Orphan Drug Designation for Eosinophilic Granulomatosis with Polyangiitis

US FDA grants Fasenra Orphan Drug Designation for Eosinophilic Granulomatosis with Polyangiitis

Pressmeddelanden   •   Nov 26, 2018 08:03 CET

AstraZeneca today announced that the US Food and Drug Administration has granted Orphan Drug Designation for Fasenra (benralizumab) for the treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA).

AstraZeneca provides update on the Phase III MYSTIC trial of  Imfinzi and tremelimumab in Stage IV non-small cell lung cancer

AstraZeneca provides update on the Phase III MYSTIC trial of Imfinzi and tremelimumab in Stage IV non-small cell lung cancer

Pressmeddelanden   •   Nov 16, 2018 08:02 CET

AstraZeneca and MedImmune, today announced final overall survival results for the Phase III MYSTIC trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) monotherapy and the combination of Imfinzi and tremelimumab, an anti-CTLA4 antibody, versus standard-of-care platinum-based chemotherapy in previously-untreated patients with Stage IV (metastatic)NSCLC.

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca to divest US Synagis rights to Sobi

Pressmeddelanden   •   Nov 13, 2018 08:01 CET

AstraZeneca has agreed to sell US rights to Synagis(palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncytial virus (RSV) to Swedish Orphan Biovitrum AB (publ) (Sobi). Sobi will commercialise Synagis in the US and around 130 AstraZeneca employees will transfer to Sobi as part of the transaction.

US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer  and grants Priority Review

US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer and grants Priority Review

Pressmeddelanden   •   Nov 12, 2018 08:07 CET

AstraZeneca and Merck & Co., Inc. US today announced that the US FDA has accepted a supplemental New Drug Application for Priority Review for the use of Lynparza tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following 1st-line standard platinum-based chemotherapy.

Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial

Farxiga significantly reduced hospitalisation for heart failure or CV death in a broad patient population with type-2 diabetes in the landmark DECLARE-TIMI 58 trial

Pressmeddelanden   •   Nov 10, 2018 22:48 CET

Fewer MACE events observed with Farxiga vs. placebo, but this finding did not reach statistical significance No imbalance in amputations, fractures, bladder cancer or Fournier’s gangrene with Farxiga vs. placebo

AstraZeneca PLC:s resultatrapport för de första nio månaderna och tredje kvartalet 2018

AstraZeneca PLC:s resultatrapport för de första nio månaderna och tredje kvartalet 2018

Pressmeddelanden   •   Nov 08, 2018 08:02 CET

AstraZeneca återgår till tillväxt i produktförsäljningen; nya läkemedel och tillväxtmarknaderna leder vägen

Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma

Divestment of rights to Alvesco, Omnaris and Zetonna to Covis Pharma

Pressmeddelanden   •   Nov 06, 2018 08:02 CET

AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), usedfor the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines.

The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018

The landmark DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga in patients with type-2 diabetes to be featured at AHA 2018

Pressmeddelanden   •   Nov 01, 2018 08:02 CET

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III CV outcomes trial (CVOT) DECLARE-TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company’s CVRM therapy area at the American Heart Association (AHA) Scientific Sessions, 10-12 November 2018, in Chicago, Illinois, USA.